Paradigm Therapeutics Overview

  • Founded

  • 1999

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 17

Employees
  • Latest Deal Type

  • M&A

Paradigm Therapeutics General Information

Description

Developer of drugs combining model genetics and bioinformatics. The company provides target identification and validation services based on gene knock out technology and in vivo pharmacology. The company has developed a drug discovery pipeline comprising targets and late stage pre-clinical projects in pain, CNS disorders, hormone dependent diseases such as prostate and breast cancer and metabolic diseases such as diabetes, hyperlipidemias, obesity and osteoporosis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Takeda Pharmaceutical Company
Primary Office
  • 214 Cambridge Science Park
  • Cambridge CB4 0WA
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Paradigm Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 31-Mar-2007 000.00 Completed Generating Revenue
4. Later Stage VC 07-Jul-2006 000.00 000.00 Completed Generating Revenue
3. Early Stage VC 00.000 000.00 Completed
2. Early Stage VC 09-Dec-2002 $18.9M $18.9M Completed Product Development
1. Early Stage VC 01-Dec-2000 Completed Product Development
To view Paradigm Therapeutics’s complete valuation and funding history, request access »

Paradigm Therapeutics Patents

  • 61

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Paradigm Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20070101444-A1 Ion channel Abandoned 08-Apr-2004 00000000000
US-20060242724-A1 Receptor Abandoned 08-Oct-2003 00000000000
JP-2007505617-A Receptor Pending 19-Sep-2003 00000000000
EP-1662862-A1 Receptor Withdrawn 19-Sep-2003 00000000000
CA-2539127-A1 Receptor Abandoned 19-Sep-2003 C12N15/8509
To view Paradigm Therapeutics’s complete patent history, request access »

Paradigm Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Paradigm Therapeutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Avlar BioVentures Venture Capital Minority 000 0000 000000 0
Bio*One Capital Corporate Venture Capital Minority 000 0000 000000 0
EDBI Venture Capital Minority 000 0000 000000 0
Excalibur Group Holdings Venture Capital Minority 000 0000 000000 0
Genmab Corporation Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial